Press room

10 March 2011 Lumavita anti-HPV product LMV-601 enters into Phase I

Basle, Switzerland: Lumavita announced today that LMV-601 was authorized by German regulatory authorities to enter into Phase I on healthy human volunteers.


2 February 2006 Shogoo and BioSphings announce a world-wide exclusive license agreement for SPK-0601.

Shogoo Pharmaceuticals K.K. (“Shogoo”), a Tokyo based specialty pharmaceutical company, announced today that it has signed an agreement with BioSphings AG (“BioSphings”), a Frankfurt based biopharmaceutical company, to obtain BioSphings’ intellectual property rights to develop and commercialize SPK-0601, a small molecule compound for the treatment of diseases caused by viral infection.


8 April 2002 Cancer Research Ventures, London, Assigns New Pre-clinical Candidate for Auto-immune Disorders and Cancer to BioSphings AG

Cancer Research Ventures (‘CRV’) announced today that it has signed an agreement with BioSphings AG to assign rights to a patent estate that it had formerly been appointed to commercialise. CRV has invested in many exciting early stage cancer developments, over recent years and this was the second advance CRV has taken forward on behalf of the inventor Dr. Eberhard Amtmann from The German Cancer Centre (‘DKFZ’) in Heidelberg.


2 April 2001 Targeted Drug Development
New biotech company founded with the participation of the Deutsches Krebsforschungszentrum

Dr. Eberhard Amtmann and Dr. Marc Roesel at the Deutsches Krebsforschungszentrum (German Cancer Research Center) have collaborated with chemist Dr. Otto Schuster to found BioSphings AG, a new biotechnology company. The Deutsches Krebsforschungszentrum will have shares in BioSphings.


© BioSphings AG 2006